comments morning. KT-XXX we clinical The primarily and and be announcing KT-XXX today on of my Nello. Thanks, . this new will data are focus
clinical The to abstract shortly, released. I we're And shown our available will Slide we, be abstract relating a few XX. course, abstract of that STATX at for Nello the first-in-class will full is accepted available KT-XXX, small full online highlights very be As was but poster on presentation degrader a molecule share for once ASH. mentioned, our of will happy follow-up
For XX abstract date. July cutoff context, our was data
liquid levels, and our date, cutoff dose solid of on As The of All across that included were that XX patients response. been of XX patients which tumors. have are for variety July a date. disease based today comments evaluable treated X XX
active, clinically with and STATX dose The of show protein evidence of beyond antitumor data continued the in along activity. pathway signs associated degradation with blood STATX in X levels inhibition to robust expected potential early in be humans, with abstract
dose dose level just XX of tumor levels at X, a in through where partial mouse saw X X. those X in dose X were there liquid treated mentioned, STATX-dependent at activity with Of substantial in X As evaluable saw X, tumors were cycles CTCL, patients patients a lymphoma, STATX liquid T-cell model. X the level a patient preclinical with we response after we degrader which
a a see and monotherapy cycles X patients on after tumor our X dose X activity available stable which assessment, clinical studies, in levels we disease XX expect the disease group we Among saw do is for preclinical solid to not X. based patients where at
observed, and were SAEs Importantly, no a PD perspective, and with from were were drug-related updates. consistent no DLTs Safety previous safety reported.
previously support These degraders of heterobifunctional the targeting in early factors undruggable encouraging findings for are potential diseases. implicated and transcription
and lymphomas in and beyond leukemias ongoing, the abstract. T-cell present to malignancies, solid what is and with therefore, data additional Accrual in hematological is we including expect patients tumors
of at We of next to month time after as presentation. look the publication as more at both poster ASH details, abstract the meeting well providing today, the forward the the
September, KT-XXX PTCL. lymphoma this it relapsed/refractory treatment happy T-cell peripheral of further Track cutaneous We're the Additionally, undruggable FDA that gave highlights the degrading cell FDA a that and designation historically CTCL to announced the we for as that of program for has granted for with treatment patients promise STATX, lymphoma. designation Fast relapsed/refractory been T-cell protein the in of the and
our to now degrader. KT-XXX, Turning MDMX
We A of time data clinical the Phase first for disclosing morning. the Ia this Arm ongoing from are trial
are initial dose activity in We that just clinical have and signs of pleased clinical we first demonstrated of to patients. mechanism proof KT-XXX levels in the report X
presentation in our results posted that our slides briefly section can take the but We of corporate the of have website, some in we summarize in and I IR Q&A. will highlight questions
tumor XX, it on common of regulator cancer intact Slide to XX% KT-XXX of that growth. remains shown the the its meaning modulate degrades retains MDMX, crucial ability to most suppressor pXX. cell cancers, pXX As close and
pXX loop that feedback repress to a protein to efficacy. pXX, inhibitors stabilize small which therefore While induce been expression. molecule increases and have They can upregulate developed limit been MDMX found and have their levels,
overcome to and thereby with MDMX pathway ability brief the shown even has KT-XXX the feedback studies, the pXX preclinical In exposures. robustly activate loop,
As KT-XXX in on shown molecule fold XX, more upregulating MDMX cancer wild-type and Slide than pXX XXX pXX, inhibitors potent cells. is killing small than greater
shows of molecule enables for maximum cells, pXX for period small normal cells models AML and doses XX to just results the more upregulates And engagement tumors target to rapid tumor activates KT-XXX time in to small KT-XXX therapeutic leading that of activation index strategy responses this intermittent MDMX to antitumor order translates in that KT-XXX. Slide support pathway compared pXX in and into inhibitors. while improve impact MDMX mitigating the molecule vivo, of dosing effectively a These apoptosis, in in in single inhibitors. relative an ALL with limited
Ia study, X refractory high-grade evaluate Phase KT-XXX As shown to doses ALL, tolerability, and patients intended Slide every is escalation us identify weeks. to tumors relapsed and lymphomas activity, is study or with dose. safety, an solid clinical II malignancies, on of once Phase KT-XXX IV adult PK/PD, the myeloid recommended the open-label initial The XX, and allow where receive trial dose
of Arm and It in B KT-XXX malignancies with and ALL. advanced with A is with is patients including arm. lymphomas comprised of X in is doses relapsed/refractory and AML Arm patients ascending solid each tumors Arms, myeloid in high-grade
Enrollment A. dose also recently to A, and Arm Arm has the X demonstration initiated have enrolled been X We X of in Arm dose to ongoing. first dosed levels B and of Arm on A, patient first with first following the on-target level pharmacology in enrollment dose fully our levels
X levels have As and a through to enrolled cutoff data a of A, of Arm been of X.X dose X of October with mean solid of cycles. cycles a have date, X total the tumors on received XX X with range X patients to
serves of mechanism As as following such, in a has upregulation pXX, shown is of the proof dose levels, as pXX it plasma and Slide GDFXX degradation. transcriptional of first target already demonstrated been XX, a upregulation with X downstream levels. in GDFXX of MDMX exposure-dependent biomarker
increase maximum increase in levels cycle X, between X, dose plasma KT-XXX in and In was levels over GDFXX and X addition in dose in level the level proportional cycle during X X to XX X. dose the baseline XX dose fold
GDFXX dose over level is the The the X This shown consistent followed towards with cycle the dosing antitumor Slide subsequent preclinical pXX X, hours on a X was of on recovery days. subject following baseline brisk associated XX, with kinetics in change XX upregulation first dose for the a KT-XXX activation after activity. by pattern of over where models was
there cycles with cycles, the X disease after for after were X, confirmed expect encouraged X study all stable progression XX. X a patient X, dose for with solid X that Even level and based though available were after dose after from within treatment and clinically patient subsequently of did disease Clinical see patients exposures, partial X after cohort X X patients on cycles tumor response, response on X. X level this cycle Slide dose dose be response treated cycles among for shown continuing the to level confirmed to we on we not was discontinued with results the active, lack are
Merkel patient as with different The response checkpoint cell had who metastatic chemotherapy with well immune multiple and had inhibitors. partial skin as abdominal been previously to lymph treated nodes a carcinoma,
XX% XX, skin nodal was responding There first reduction the were metastases cycles after shown As approximately no tumor the resolution after metastasis. cycles, of the And in Slide on node burden of there lymph as were was dose-limiting an X and toxicities. treatment the skin metastasis. X
during deemed up of to XX, without As X the dose who reduction X Slide SAE cycles X study patients an occurring drug. X, on were related hypotension intake drug-related fluids grade due recurrence in more of X nausea, patient the therapy. Treatment grade X AEs IV shown to was that most oral thrombocytopenia at diminished or AEs grade or received in X dose common included diarrhea. X even patients There no or neutropenia in on and had study patient remains included had X hypotension. cycle to level of
XX, of and degraders, of to hematological for to these along Slide on of clinical summary, evidence therapeutic pathway therapeutic interim activity MDMX inhibitors. and hypothesis small including typical In toxicity, the engagement promising molecule activation, are compared DLTs, showing target initial with signs pXX improve supportive our antitumor potential data index MDMX without the
impacting and As also comprehensive of are we the data clinical continue to and in different examining dosing order liquid explore with to of Phase biomarkers for in we clinical the safety preclinical tumor and intermittent response Ia. development tumors across after Ia, to KT-XXX vivo selection activity together solid a KT-XXX next types the patient factors in liquid multiple in putting and both solid set stage Phase derive
well as planned additional is XXXX. as selection clinical preclinical data a of informing strategy Disclosure biomarker-based for patient data,
IRAKX which development Phase of direction II our our the under partner, on update is degrader, quick KT-XXX, Sanofi. a in Finally, now
disclosed, in has for dosed, the significant trial patient been the milestone are first the we and excited we recently about Kymera. HS As
news commenced, In will that dosed addition, trial we in after and the AD it of occurs. first the recently trial report patient
The have details the a study are both summary clinicaltrials.gov, XX. designs Slide on around on for we and available trials
will and both KT-XXX I for assessment Dose our a to safety, PD. the the will trials informed weeks. high versus level, from patient a was powered show and placebo on-target XX also data PD effect the efficacy in relative study, trials treatment safety of and comprehensive a evaluate and by are to cohort Phase placebo clinical At provide escalation
study HS and enroll endpoints lesion XXX studies these and up Both study HiSCR, to IHSX, HS count, AN patients, and skin the will measuring approximately In measures. XXX the standard burden patients. symptoms. include up AD to The include pain study,
AD the along score, in and measures. include While EASI Pruritus with these trial, vIGA-AD
advance Phase our AD to with into patient Both see represent excited II. needs, program HS partner, and unmet indications Sanofi, we're important and significant the
both XXXX. anticipating of QX half completion enrollment completion in in top As have noted data in first trials line dates clinicaltrials.gov in XXXX, primary posting, XXXX, the the and of
and discussion Bruce I'll here the the pause to financials. review turn to
